Compare Johnson & Johnson (JNJ) vs Nike Inc (NKE) Price & Performance

Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.

JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.

Nike (NKE) trades at $43.47, down 0.66% on the day, with a bearish technical signal from moving averages. The company reported revenue of $46.31 billion for 2025, with net income of $3.22 billion, though margins have compressed from prior years. Recent quarterly earnings have consistently beaten expectations, and a dividend of $0.41 is scheduled for July 2026. Analyst consensus is a Buy with a $50.80 price target, but news highlights challenges in China and EMEA markets.

The outlook is mixed: strong brand equity and earnings beats support upside, but revenue growth concerns and competitive pressures pose risks. Investors should weigh the 22.14% ROE against margin trends and macroeconomic headwinds affecting consumer demand.